The National Pharmaceutical Pricing Authority (NPPA) approved an increase in the price of 11 formulations of eight drugs to ...

Myopia control spectacles have not yet secured US FDA approval, but these treatments show promise for limiting myopia ...

Myopia, or shortsightedness, is rapidly increasing among children worldwide, with projections showing it could affect over 40 ...

Nearsightedness, or myopia, is becoming increasingly prevalent worldwide, affecting millions of individuals and posing ...

Childhood myopia has emerged as a global public health concern, with its prevalence rapidly increasing worldwide. Myopia is typically diagnosed in early childhood and often progresses throughout ...

An increase in myopia progression was observed among Chicago-area children early in the COVID-19 pandemic, reported ...

Atropine and morphine abolish this contraction; but the mechanism of the action of these two drugs appears to be different. The following experiments show that whereas atropine apparently acts by ...

You will have one to three drops put directly into each eye. Depending on what your provider is trying to see and how large your pupil needs to be, different types of eye drops can be used: ...

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and ...

CHAPERONE is Eyenovia’s Phase 3 study evaluating its proprietary drug-device combination of low-dose atropine in the Company’s Optejet dispensing platform as a potential treatment for ...

Increased attention and further investigation seem warranted in the management of myopia progression in children with IXT, prompting this evaluation of low-concentration atropine in children with IXT, ...

A new study published in Asia-Pacific Journal of Ophthalmology has explored the relationship between short term atropine use in childhood and choroidal thickness as an adult. An international team of ...